Cellular therapy Gilbert: the real question is whether it buys you time before the replacement

Everyday wear often explains a steady ache

A worn joint may hurt when you stand, climb stairs, reach overhead, or get up from a chair. It'll often feel stiff after sitting. Extra work may bring more soreness that evening. That doesn't always mean the joint is badly damaged.

What matters now is change. If the ache keeps growing, wakes you, or hurts while you rest, don't keep guessing. An exam can find the tender area and test how the joint moves. You won't always need an X-ray, but it may help your doctor judge the wear.

Notice what starts the soreness and what calms it. Those details will help during your exam.

Gentle care can calm a common flare

After you overdo it, a few quieter days may help. Gentle movement is often easier on the joint than a full day without moving. Heat may loosen stiffness, while cold may settle swelling after activity. A brace or cane may take some strain off.

Don't force your way through a sharp flare. Split a long chore into smaller jobs, and stop before tomorrow's soreness gets worse. If medicine might help, ask your doctor what is safe with the pills you already take.

Start with what is simple and safe.

QC Kinetix offers care without surgery

If home care isn't enough, QC Kinetix offers a consultation about regenerative treatments for joint soreness. That's non-surgical clinic care. The term medical providers means clinic staff who examine your joint and carry out the procedure. PRP may be used in one procedure: your blood goes through a spinner until the plasma, its liquid part, holds more platelets, small blood parts that gather at a cut, then the provider places the prepared blood in the aching joint.

The Chandler clinic serves Gilbert residents, and the consultation costs nothing. You'll be asked where it hurts, how long it has hurt, and which movements add soreness. The provider will examine the joint and explain whether the clinic procedure fits. It won't fit every joint.

Nobody knows how much relief you'll get.

Sources

1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

2. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

3. A systematic review of 21 studies re-examining the familiar '20 percent are dissatisfied after knee replacement' figure found the actual average dissatisfaction rate was 10 percent, and 7.3 percent when complications were excluded - the surgical benchmark a cash-pay injection is implicitly competing against.

   DeFrance MJ, et al. — Are 20% of Patients Actually Dissatisfied Following Total Knee Arthroplasty? A Systematic Review of the Literature. J Arthroplasty, 2023. DOI: 10.1016/j.arth.2022.10.011.

4. The AAOS Surgical Management of Osteoarthritis of the Knee clinical practice guideline sets out 16 recommendations and seven options for surgical management based on a systematic review of the published evidence - the reference point for when a joint has moved past the injectable tier.

   Srivastava AK, et al. — American Academy of Orthopaedic Surgeons Clinical Practice Guideline Summary of Surgical Management of Osteoarthritis of the Knee. J Am Acad Orthop Surg, 2023. DOI: 10.5435/JAAOS-D-23-00338.

5. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

6. A meta-analysis of 14 placebo cohorts across 13 Level I trials in 1,076 knee osteoarthritis patients found that intra-articular saline - the placebo - produced pain and function improvements exceeding the minimal clinically important difference at 3 and 6 months.

   Saltzman BM, et al. — The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies. Am J Sports Med, 2017. DOI: 10.1177/0363546516680607.

7. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

8. The 2018 AAOS/NIH consensus work group recommended that minimally manipulated mixed cell preparations be called CELL THERAPY rather than stem cell therapy, and that their untested and uncharacterised nature be clearly communicated to patients and the public, because stem cells have properties these preparations do not meet.

   Chu CR, et al. — Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg, 2019. DOI: 10.5435/JAAOS-D-18-00305.